Alumni
Spago Nanomedical
Spago Nanomedical is a Swedish clinical phase company, developing products for treatment and imaging diagnostics of cancer and other severe diseases. The company’s main focus is on advancing Tumorad, a novel radionuclide therapy for aggressive cancers, and SpagoPix, a selective MRI contrast agent designed to improve diagnostic precision in patients with suspected endometriosis and cancer.

Mats Hansen holds a Ph.D. in plant biochemistry and a Master in biology. He has extensive experience in project management, clinical development and business development within oncology pharmaceuticals. His prior roles include director of Project Management and Head of Knowledge Management at Active Biotech AB, where he previously also has held various positions within information management, IP and business development. Mats is also member of the board of Ekoscandica Naturguide AB.



















































